Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

Journal of Clinical Oncology

Volumn 27, Issue 3, 2009, Pages 418-425

  Berek, Jonathan ^a   Taylor, Peyton ^a   McGuire, William ^a   Smith, L Mary ^a   Schultes, Birgit ^a   Nicodemus, Christopher F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; MONOCLONAL ANTIBODY; OREGOMOVAB; PACLITAXEL; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; CANCER FATIGUE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CA-125 ANTIGEN; CARBOPLATIN; FEMALE; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 58549088720     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.8400     Document Type: Article

References (23)

1. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 334:1-6, 1996
2. Ozols RF: Systemic therapy for ovarian cancer: Current status and new treatments. Semin Oncol 33:S3-S11, 2006
3. Bookman M: GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG- liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 24:256s, 2006 (suppl; abstr 5002)
4. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003
5. Conte P, Favalli G, Gadducci A, et al: Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT). J Clin Oncol 25:275s, 2007 (suppl; abstr 5505)
6. Markman M, Liu P, Wilczynski S, et al: Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (c) of monthly single-agent paclitaxel (PAC) (PLAT)/PAC. J Clin Oncol 24:257s, 2006 (suppl; abstr 5005)
7. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
8. Berek JS, Taylor PT, Gordon A, et al: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22:3507-3516, 2004
9. Braly P, Chu C, Collins Y, et al: Prospective evaluation of front-line chemo-immunotherapy (C-IT) with oregovomab (2 alternative dosing schedules) carboplatin-paclitaxel (C-P) in advanced ovarian cancer (OC). J Clin Oncol 25:123s, 2007 (suppl; abstr 3024)
10. Gordon AN, Schultes BC, Gallion H, et al: CA125 and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 94: 340-351, 2004
11. Nicodemus CF, Smith LM, Schultes BC: Role of monoclonal antibodies in tumor-specific immunity. Expert Opin Biol Ther 7:331-343, 2007
12. Taylor PT, Haverstick D: Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 97:151, 2005
13. Schultes BC, Baum RP, Niesen A, et al: Antiidiotype induction therapy: Anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immu-nother 46:201-212, 1998
14. Kaplan EL, Meier W: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al: Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19:1809-1817, 2001
16. Berek JS, Taylor PT, Nicodemus C: CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother 31:207-214, 2008
17. Berd D, Sato T, Maguire HC Jr, et al: Immu-nopharmacologic analysis of an autologous, hapten- modified human melanoma vaccine. J Clin Oncol 22:403-415, 2004
18. Emens LA, Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65:8059-8064, 2005
19. Lutsiak MEC, Semnani RT, De Pascalis R, et al: Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868, 2005
20. Sakaguchi S, Sakaguchi N, Shimizu J, et al: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18-32, 2001
21. Trumpfheller C, Caskey M, Nchinda G, et al: The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a
22. dendritic cell targeted vaccine. Proc Natl Acad Sci USA 105:2574-2579, 2008
23. Yang JC, Hughes M, Kammula U, et al: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825-830, 2007